Who can benefit?

 

 

 


  

 

The challenge of idiosyncratic DILI

 

 

Idiosyncratic DILI is a major issue in late stage drug development

 

1) DILI is a rare event:

- it affects only susceptible patients due to their individual characteristics, it can not be predicted

- it becomes evident when an increasing number of individuals is treated

 

2) DILI is difficult to diagnose and drug causality may impossible to determine in patients taking several drugs

- diagnosis of exclusion & impossible causality in polymedication ► no possibility to clear DILI suspicion from a drug

- failure to correctly diagnose DILI or adjudicate causality ► lack of biomarkers to rescue a drug with DILI issues